Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Concentration is lot-specific and will vary from 0.5-0.6 mg/ml
4E-BP1 (Eukaryotic initiation factor 4E binding protein 1, PHAS) is a 20 kDa translation repressor protein, and directly interacts with eukaryotic translation initiation factor 4E (eIF4E), which is a limiting component of the multi-subunit complex that recruits 40S ribosomal subunits to the 5' end of mRNAs. 4E-BP1 inhibits cap-dependent translation by binding to eIF4E on the same site that overlaps the binding site for eIF4G, preventing its binding to the latter and leading to an increase in mRNA translation. The phosphorylation of 4E-BP1 is critical in determining cell fate by controlling translation initiation and apoptotic potency. 4E-BP1 is hyper-phosphorylated in response to several external stimuli including hormones, growth factors, mitogens, cytokines and G-protein-coupled receptors and in response to stress conditions including nutrient deprivation. The phosphorylation of these sites is believed to occur in an orderly fashion where phosphorylation of threonine 37 and 46 by FRAP/mTOR is a priming step for subsequent phosphorylation of 4E-BP1 at the carboxy-terminal sites. Under normoxic conditions, increased VEGF expression, resulting from inhibition of 4E-BP1, contributes to efficient angiogenesis and metastatic brain growth through activated integrin alpha-v beta3. 4E-BP1 is phosphorylated in response to various signals including UV irradiation and insulin signaling, resulting in its dissociation from eIF4E and activation of mRNA translation.
仅用于科研。不用于诊断过程。未经明确授权不得转售。